CorMedix Statistics
Total Valuation
CorMedix has a market cap or net worth of $861.77 million. The enterprise value is $675.39 million.
| Market Cap | 861.77M |
| Enterprise Value | 675.39M |
Important Dates
The next estimated earnings date is Wednesday, October 29, 2025, before market open.
| Earnings Date | Oct 29, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CorMedix has 78.06 million shares outstanding. The number of shares has increased by 13.87% in one year.
| Current Share Class | 78.06M |
| Shares Outstanding | 78.06M |
| Shares Change (YoY) | +13.87% |
| Shares Change (QoQ) | +4.27% |
| Owned by Insiders (%) | 7.00% |
| Owned by Institutions (%) | 44.91% |
| Float | 72.60M |
Valuation Ratios
The trailing PE ratio is 13.95 and the forward PE ratio is 4.94.
| PE Ratio | 13.95 |
| Forward PE | 4.94 |
| PS Ratio | 5.88 |
| Forward PS | 2.28 |
| PB Ratio | 3.81 |
| P/TBV Ratio | 3.95 |
| P/FCF Ratio | 28.47 |
| P/OCF Ratio | 28.42 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.55, with an EV/FCF ratio of 22.21.
| EV / Earnings | 13.20 |
| EV / Sales | 5.56 |
| EV / EBITDA | 13.55 |
| EV / EBIT | 13.69 |
| EV / FCF | 22.21 |
Financial Position
The company has a current ratio of 7.82, with a Debt / Equity ratio of 0.00.
| Current Ratio | 7.82 |
| Quick Ratio | 7.37 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | 0.01 |
| Debt / FCF | 0.01 |
| Interest Coverage | 1,344.06 |
Financial Efficiency
Return on equity (ROE) is 38.35% and return on invested capital (ROIC) is 23.02%.
| Return on Equity (ROE) | 38.35% |
| Return on Assets (ROA) | 19.86% |
| Return on Invested Capital (ROIC) | 23.02% |
| Return on Capital Employed (ROCE) | 22.33% |
| Revenue Per Employee | $1.87M |
| Profits Per Employee | $787,069 |
| Employee Count | 65 |
| Asset Turnover | 0.78 |
| Inventory Turnover | 0.78 |
Taxes
In the past 12 months, CorMedix has paid $521,507 in taxes.
| Income Tax | 521,507 |
| Effective Tax Rate | 1.01% |
Stock Price Statistics
The stock price has increased by +14.58% in the last 52 weeks. The beta is 1.85, so CorMedix's price volatility has been higher than the market average.
| Beta (5Y) | 1.85 |
| 52-Week Price Change | +14.58% |
| 50-Day Moving Average | 12.25 |
| 200-Day Moving Average | 11.08 |
| Relative Strength Index (RSI) | 41.92 |
| Average Volume (20 Days) | 2,543,978 |
Short Selling Information
The latest short interest is 16.67 million, so 21.36% of the outstanding shares have been sold short.
| Short Interest | 16.67M |
| Short Previous Month | 11.89M |
| Short % of Shares Out | 21.36% |
| Short % of Float | 22.97% |
| Short Ratio (days to cover) | 3.73 |
Income Statement
In the last 12 months, CorMedix had revenue of $121.48 million and earned $51.16 million in profits. Earnings per share was $0.79.
| Revenue | 121.48M |
| Gross Profit | 116.16M |
| Operating Income | 49.32M |
| Pretax Income | 51.68M |
| Net Income | 51.16M |
| EBITDA | 49.85M |
| EBIT | 49.32M |
| Earnings Per Share (EPS) | $0.79 |
Balance Sheet
The company has $190.71 million in cash and $435,245 in debt, giving a net cash position of $190.28 million or $2.44 per share.
| Cash & Cash Equivalents | 190.71M |
| Total Debt | 435,245 |
| Net Cash | 190.28M |
| Net Cash Per Share | $2.44 |
| Equity (Book Value) | 220.63M |
| Book Value Per Share | 2.96 |
| Working Capital | 216.35M |
Cash Flow
In the last 12 months, operating cash flow was $30.46 million and capital expenditures -$53,757, giving a free cash flow of $30.41 million.
| Operating Cash Flow | 30.46M |
| Capital Expenditures | -53,757 |
| Free Cash Flow | 30.41M |
| FCF Per Share | $0.39 |
Margins
Gross margin is 95.62%, with operating and profit margins of 40.60% and 42.11%.
| Gross Margin | 95.62% |
| Operating Margin | 40.60% |
| Pretax Margin | 42.54% |
| Profit Margin | 42.11% |
| EBITDA Margin | 41.04% |
| EBIT Margin | 40.60% |
| FCF Margin | 25.03% |
Dividends & Yields
CorMedix does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -13.87% |
| Shareholder Yield | -13.87% |
| Earnings Yield | 5.91% |
| FCF Yield | 3.51% |
Analyst Forecast
The average price target for CorMedix is $17.57, which is 59.15% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $17.57 |
| Price Target Difference | 59.15% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (5Y) | 61.01% |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on March 26, 2019. It was a reverse split with a ratio of 1:5.
| Last Split Date | Mar 26, 2019 |
| Split Type | Reverse |
| Split Ratio | 1:5 |
Scores
CorMedix has an Altman Z-Score of 11.11 and a Piotroski F-Score of 6.
| Altman Z-Score | 11.11 |
| Piotroski F-Score | 6 |